A 2023 test showing that Novo Nordisk (NYSE: NVO )’s Wegovy weight-loss medication not only helped people lose weight but ...

Research on weight loss drugs like Ozempic shows varied results for mental health impacts, with some patients experiencing ...

Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...

While the US leads in early-phase obesity trials and investment, the country also faces challenges in disease burden, trial ...

Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...

For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can ...

Danish drugmaker Novo Nordisk is teaming up with California-based biotech Septerna to develop new pills to treat obesity, ...

The side effects of the two drugs combined include dizziness, abnormal sensations, altered taste, insomnia, constipation and ...

The common theme at the maker of Wegovy and at UnitedHealth may be investors' sudden awareness of cost-cutting pressure.

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...